Updated Jul 16, 2026
GRAF FINCKENSTEIN FRIEDRICH has filed 2 SEC Form 4 filings across 1 company in the last 90 days.
Friedrich Graf Finckenstein is the Chief Medical Officer at Iovance Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on cancer therapies. He has been involved in the company's efforts to develop personalized T-cell therapies for cancer treatment.
| Role | Chief Medical Officer |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-09 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | F — Tax withholding / forfeiture | 4.0K | $4.23 | $17K |
| 2026-06-09 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | M — Option exercise | 7.8K | $0.00 | |
| 2026-06-03 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | F — Tax withholding / forfeiture | 4.5K | $3.96 | $18K |
| 2026-06-03 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | M — Option exercise | 8.8K | $0.00 | |
| 2026-03-06 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | F — Tax withholding / forfeiture | 16.5K | $4.58 | $76K |
| 2026-03-06 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | M — Option exercise | 31.2K | $0.00 | |
| 2026-03-04 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | F — Tax withholding / forfeiture | 7.1K | $3.79 | $27K |
| 2026-03-04 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | M — Option exercise | 12.7K | $0.00 | |
| 2025-09-02 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | F — Tax withholding / forfeiture | 6.4K | $2.19 | $14K |
| 2025-09-02 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | M — Option exercise | 12.7K | $0.00 | |
| 2024-12-04 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | F — Tax withholding / forfeiture | 2.0K | $9.07 | $18K |
| 2024-12-04 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | M — Option exercise | 3.9K | $0.00 | |
| 2024-10-16 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | F — Tax withholding / forfeiture | 1.4K | $9.77 | $14K |
| 2024-10-16 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | M — Option exercise | 2.8K | $0.00 |
Friedrich Graf Finckenstein is the Chief Medical Officer at Iovance Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on cancer therapies. He has been involved in the company's efforts to develop personalized T-cell therapies for cancer treatment.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live GRAF FINCKENSTEIN FRIEDRICH profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.